PetDx, Inc.
About PetDx, Inc.
Company overview
PetDx is a biotechnology company specializing in the field of liquid biopsy for veterinary medicine. Focused on revolutionizing the diagnostic landscape in veterinary care, PetDx harnesses the power of liquid biopsy technology to provide accurate and non-invasive diagnostic solutions for pets. With a strong emphasis on precision medicine, the company aims to improve the early detection, monitoring, and treatment of diseases in companion animals. Product/Service Line Breakdown: Liquid Biopsy Testing: PetDx offers advanced liquid biopsy tests specifically tailored for veterinary applications. Liquid biopsy is a non-invasive diagnostic technique that analyzes biofluids such as blood, urine, or saliva to detect and monitor various diseases in pets. PetDx's liquid biopsy tests utilize cutting-edge technologies, including next-generation sequencing and molecular profiling, to identify genetic mutations, biomarkers, and other indicators of diseases such as cancer, infectious diseases, and genetic disorders. Disease Monitoring and Treatment Guidance: Through the analysis of liquid biopsy samples, PetDx provides valuable insights into disease progression and treatment response. By monitoring genetic alterations and biomarkers over time, veterinarians can make informed decisions regarding personalized treatment plans, drug selection, and therapeutic interventions. PetDx's comprehensive reports and expert consultations assist veterinary professionals in tailoring patient care for improved outcomes. Research and Development: PetDx places a strong emphasis on research and development to continually advance liquid biopsy technology in veterinary medicine. Through ongoing innovation and collaboration with academic institutions and veterinary professionals, PetDx strives to enhance the accuracy, sensitivity, and applicability of liquid biopsy tests. By staying at the forefront of scientific advancements, PetDx aims to expand its diagnostic capabilities and improve the overall quality of veterinary care. Veterinary Education and Training: PetDx is dedicated to providing educational resources and training programs to veterinary professionals. These initiatives aim to increase awareness and understanding of liquid biopsy technology, its applications, and its benefits in veterinary medicine. By empowering veterinarians with the knowledge and skills necessary to interpret liquid biopsy results, PetDx supports the integration of this innovative diagnostic approach into routine veterinary practice. Collaborative Partnerships: PetDx actively seeks partnerships and collaborations with veterinary clinics, research institutions, and industry stakeholders. By fostering collaborations, PetDx aims to accelerate the adoption and implementation of liquid biopsy technology in veterinary care. These partnerships may involve joint research projects, data-sharing initiatives, and the co-development of novel liquid biopsy-based diagnostic tools and solutions. Laboratory Services: PetDx operates state-of-the-art diagnostic laboratories equipped with cutting-edge technologies and staffed by skilled scientists and technicians. The company performs all liquid biopsy testing in-house, ensuring rigorous quality control and efficient turnaround times for test results. This vertically integrated laboratory infrastructure enables PetDx to provide reliable and timely diagnostic services to veterinary professionals.
Keywords
Revenue
EBITDA
Valuation
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenues | $380 MM | $250 MM | $90 MM | $120 MM | $65 MM |
| Gross Profit | $190 MM | $125 MM | $45 MM | $60 MM | $32.50 MM |
| Net Income (Loss) | $43 MM | $25 MM | $9 MM | $12 MM | $6.50 MM |
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $850 MM | $720 MM | $680 MM | $650 MM | $600 MM |
| Total Liabilities | $450 MM | $400 MM | $380 MM | $350 MM | $320 MM |
| Total Equity | $400 MM | $320 MM | $300 MM | $300 MM | $280 MM |
Ratios
Employee Figures
Key Executives
See All401K
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
© 2026 PrivCo Holding Inc. All rights reserved.
No AI Training or Automated Data Extraction.
Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.